Loading organizations...
§ Private Profile · Luz Soriano 67, Lisbon, Lisbon, 1200-246, Portugal
Portuguese medical cannabis company cultivating, processing, and extracting organic medical cannabis for the European market, using EU-GMP facilities.
AceCann is an agritech and pharmaceutical company based in Lisbon, Portugal, focused on the cultivation, processing, and extraction of organic medical cannabis products for the European healthcare market. The business utilizes advanced indoor farming technology and clean extraction methods at its newly constructed Vendas Novas production facility to supply standardized medical cannabis flowers and extracts to pharmaceutical distributors. To support its infrastructure and research initiatives, the enterprise has raised $15 million in total seed funding. This financing was led by Snoop Dogg's investment firm Casa Verde Capital, with additional participation from Lince Capital, Advanced Nutrients, and Advanced Grow Labs founders Chris Mayle and Marc Gare. The organization also holds a research and development certificate of suitability from the Portuguese National Innovation Agency. AceCann was founded in 2019 by Diogo Carvalho and Antonin Cohen.
AceCann has raised $15.0M across 1 funding round.
AceCann has raised $15.0M in total across 1 funding round.
AceCann has raised $15.0M across 1 funding round. Most recently, it raised $15.0M Seed in October 2021.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Oct 1, 2021 | $15M Seed | Casa Verde Capital | Chris Mayle, Frank C., Marc Gare, Sebastian DE LA Rosa, Lince Capital | Announced |
AceCann is a Portuguese medical cannabis company specializing in the organic cultivation, processing, extraction, and research & development of premium medical cannabis products for the European market. It serves patients requiring medical cannabis by providing high-quality, pharmaceutical-grade products that aim to improve health outcomes and quality of life. AceCann addresses the challenge of inconsistent and low-quality cannabis products in Europe by using unique organic indoor cultivation techniques and solvent-free extraction technology to maximize cannabinoid and terpene content, ensuring product consistency and efficacy. The company is experiencing growth momentum, supported by a $15 million seed funding round in 2021, which is accelerating the development of a state-of-the-art indoor production facility expected to generate significant annual sales by 2024[1][2][3].
Founded in 2019 in Lisbon, Portugal, AceCann was established by a team with expertise in cannabis cultivation and pharmaceutical manufacturing. The idea emerged from the recognition of a growing demand for high-quality medical cannabis in Europe and the lack of premium, consistent products in the market. Early traction included securing significant seed funding led by Casa Verde Capital, marking their first European investment, and obtaining Portugal’s first R&D certificate of suitability from the National Innovation Agency. These milestones enabled AceCann to pivot towards indoor cultivation, differentiating itself from other European projects and positioning for rapid growth as legalization expands across Europe[1][3].
AceCann is riding the wave of increasing legalization and acceptance of medical cannabis across Europe, a market projected to reach $3.4 billion by 2024. The timing is critical as more European countries adopt medical cannabis frameworks, creating a rapidly expanding patient base. Market forces such as rising patient access, demand for pharmaceutical-grade products, and innovation in cannabis delivery platforms favor AceCann’s growth. By pioneering organic indoor cultivation and pharmaceutical processing standards in Europe, AceCann influences the broader ecosystem by setting new quality benchmarks and accelerating the professionalization of the European medical cannabis industry[1][3].
AceCann is poised to become a leading premium provider in Europe’s burgeoning medical cannabis market. The completion and scaling of its indoor production facility will be a key growth driver, potentially generating €15-20 million in annual sales by 2024. Future trends shaping its journey include broader legalization, increased patient adoption, and continued innovation in cannabis-based therapies. AceCann’s emphasis on quality, sustainability, and R&D positions it well to expand its influence, possibly leading to new product categories and therapeutic applications. Its trajectory reflects the maturation of Europe’s medical cannabis sector from fragmented markets to a sophisticated, innovation-driven industry[1][3][4].
AceCann has raised $15.0M in total across 1 funding round.
AceCann's investors include Casa Verde Capital, Chris Mayle, Frank C., Marc Gare, Sebastian De La Rosa, Lince Capital.